Office Manager
Arcellx$60,000 - $80,000/year
- Full Time
- Mid-level (3 to 4 years), Junior (1 to 2 years)
About Arcellx
Arcellx develops immunotherapies aimed at improving cell therapy for serious diseases. Their products focus on advanced techniques that enhance the effectiveness of treatments. The company collaborates with healthcare providers and research institutions to bring these therapies to patients. Unlike many competitors, Arcellx emphasizes proprietary products and partnerships to drive their research and development efforts. The goal is to meet unmet medical needs by providing safe and effective treatment options through their innovative approach to cell therapy.
Gaithersburg, MarylandHeadquarters
2014Year Founded
$194.5MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
51-200Employees
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Unlimited Paid Time Off
Flexible Work Hours
401(k) Company Match
Fully-Paid Parental Leave
Tuition Reimbursement
Relocation Assistance
Risks
Competition from established CAR-T therapies like Abecma and Carvykti could limit market share.
Dependency on Gilead's Kite partnership poses risks if partnership dynamics change.
Phase 3 iMMagine-3 trial delays or failures could impact anito-cel's market timeline.
Differentiation
Arcellx's CART-ddBCMA has FDA Fast Track and Orphan Drug designations.
The novel D-Domain binder in anito-cel enhances antigen binding and cell killing.
ARC-SparX offers dosable and controllable CAR-T therapy options.
Upsides
Growing investment in personalized medicine aligns with Arcellx's tailored immunotherapies.
Advancements in gene editing like CRISPR enhance precision in engineered cell therapies.
Outpatient CAR-T administration could reduce costs and increase accessibility for Arcellx.
Funding
Total raised$194.55 M
Latest valuation$575.00 M
StageIPO
POST IPO EQUITY
10/31/2023$200
IPO
5/31/2022$129
SERIES C
3/31/2021- Novo Holdings
- SR One
- Takeda Ventures
- Sixty Degree Capital
- Cambrian BioPharma
- Clough Capital Partners
- CaaS Capital Management
- LG Technology Ventures
- Asymmetry
- Adage Capital
- Terra Magnum Capital Partners
- Surveyor Capital
- Samsara BioCapital
- NEA
- New Enterprise Associates
- Soleus Capital
- Suvretta Capital Management
- CAM Capital
$115
$575.00 M